These results do not eliminate a role for regulation of BCL2 family proteins (including BIM) in drug combination-induced AML cell killing, but do indicate that BETi-mediated repression of BCL2 is not necessary for killing by the combination. Here, BCL2 is linked to acute myeloid leukemia.